Compare Stocks: INMB, KROS, GLSI, and WHWK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$14.24 -1.0%	$19.66	$7.78 ▼ $34.10	$211.22M	1.46	169,441 shs	87,617 shs
INMB INmune Bio	$1.91 +0.5%	$1.61	$1.09 ▼ $2.85	$50.51M	0.97	561,201 shs	233,316 shs
KROS Keros Therapeutics	$10.65 +6.6%	$10.62	$9.69 ▼ $22.55	$198.17M	0.99	200,678 shs	386,631 shs
WHWK Whitehawk Therapeutics	$4.70 +15.5%	$4.11	$1.57 ▼ $5.49	$201.27M	0.76	431,950 shs	308,563 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	-1.04%	+1.57%	-23.32%	-37.71%	+17.69%
INMB INmune Bio	+0.53%	+7.91%	+9.77%	+33.57%	-30.80%
KROS Keros Therapeutics	+6.61%	+4.21%	-8.58%	-11.76%	-26.09%
WHWK Whitehawk Therapeutics	+15.48%	+22.08%	+13.25%	+18.39%	+161.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$14.24 -1.0%	$19.66	$7.78 ▼ $34.10	$211.22M	1.46	169,441 shs	87,617 shs
INMB INmune Bio	$1.91 +0.5%	$1.61	$1.09 ▼ $2.85	$50.51M	0.97	561,201 shs	233,316 shs
KROS Keros Therapeutics	$10.65 +6.6%	$10.62	$9.69 ▼ $22.55	$198.17M	0.99	200,678 shs	386,631 shs
WHWK Whitehawk Therapeutics	$4.70 +15.5%	$4.11	$1.57 ▼ $5.49	$201.27M	0.76	431,950 shs	308,563 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	-1.04%	+1.57%	-23.32%	-37.71%	+17.69%
INMB INmune Bio	+0.53%	+7.91%	+9.77%	+33.57%	-30.80%
KROS Keros Therapeutics	+6.61%	+4.21%	-8.58%	-11.76%	-26.09%
WHWK Whitehawk Therapeutics	+15.48%	+22.08%	+13.25%	+18.39%	+161.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	300.28% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
KROS Keros Therapeutics	2.22	Hold	$20.50	92.49% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	74.47% Upside

Current Analyst Ratings Breakdown

Latest INMB, KROS, GLSI, and WHWK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
6/25/2026	WHWK Whitehawk Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/11/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/5/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
INMB INmune Bio	$50K	1,015.36	N/A	N/A	$0.88 per share	2.17
KROS Keros Therapeutics	$244.06M	0.87	$4.82 per share	2.21	$13.23 per share	0.80
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-941.15%	-368.53%	8/13/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$1.67	N/A	N/A	N/A	N/A	-103.03%	-77.66%	8/6/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	N/A
WHWK Whitehawk Therapeutics	-$20.60M	-$1.68	N/A	N/A	N/A	N/A	-79.63%	-74.01%	N/A

Latest INMB, KROS, GLSI, and WHWK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A
5/14/2026	Q1 2026	KROS Keros Therapeutics	-$1.0229	-$1.21	-$0.1871	-$1.21	$1.93 million	$0.37 million
5/7/2026	Q1 2026	INMB INmune Bio	-$0.2450	-$0.20	+$0.0450	-$0.20	$1.11 million	N/A
5/7/2026	Q1 2026	WHWK Whitehawk Therapeutics	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLSI Greenwich LifeSciences	N/A	2.01	2.01
INMB INmune Bio	N/A	4.24	4.24
KROS Keros Therapeutics	N/A	21.96	22.62
WHWK Whitehawk Therapeutics	N/A	11.36	11.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLSI Greenwich LifeSciences	4.16%
INMB INmune Bio	12.72%
KROS Keros Therapeutics	71.56%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
GLSI Greenwich LifeSciences	51.47%
INMB INmune Bio	21.40%
KROS Keros Therapeutics	12.60%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
INMB INmune Bio	10	26.58 million	20.90 million	Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable
WHWK Whitehawk Therapeutics	21	49.45 million	24.78 million	N/A

INMB, KROS, GLSI, and WHWK Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

4 hours ago | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6 at 12:51 PM | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6 at 8:00 AM | prnewswire.com

Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

July 30, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 30, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts

July 25, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest

July 14, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners

July 13, 2026 | marketbeat.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 15, 2026 | prnewswire.com

Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know

May 14, 2026 | theglobeandmail.com

Whitehawk Therapeutics secures $87.5M PIPE financing

May 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, KROS, GLSI, and WHWK Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

$14.24 -0.15 (-1.04%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$14.24 -0.01 (-0.04%)

As of 08/6/2026 05:18 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

INmune Bio NASDAQ:INMB

$1.91 +0.01 (+0.53%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$1.94 +0.03 (+1.47%)

As of 08/6/2026 06:48 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Keros Therapeutics NASDAQ:KROS

$10.65 +0.66 (+6.61%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$10.64 -0.01 (-0.09%)

As of 08/6/2026 04:20 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Whitehawk Therapeutics NASDAQ:WHWK

$4.70 +0.63 (+15.48%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$4.57 -0.13 (-2.77%)

As of 08/6/2026 06:45 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, KROS, GLSI, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, KROS, GLSI, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, KROS, GLSI, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, KROS, GLSI, and WHWK Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

INmune Bio NASDAQ:INMB

Keros Therapeutics NASDAQ:KROS

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, KROS, GLSI, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, KROS, GLSI, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, KROS, GLSI, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, KROS, GLSI, and WHWK Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

INmune Bio NASDAQ:INMB

Keros Therapeutics NASDAQ:KROS

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools